According to a new study, antibiotic use may worsen melanoma by damaging the gut microbiome.
According to a recent study by researchers at Emory University in Atlanta, the use of broad-spectrum antibiotics in mice with malignant melanoma, an aggressive type of skin cancer, accelerated their metastatic bone growth. This was most likely because the drugs depleted the mice’s intestinal flora and weakened their immune response.
According to one of the study’s authors, Subhashis Pal, Ph.D., a postdoctoral fellow in endocrinology at the Emory University School of Medicine, the findings highlight the significance of the gut microbiome in overall health and suggest that physicians should carefully consider the gastrointestinal effects when using antibiotic therapies to treat cancer or other diseases.
“Any disease or therapy that harms the gut microbiome could have a negative impact on our health,” said Dr. Pal, who presented the report today at the annual meeting of the American Society of Bone and Mineral Research in Austin, Texas, USA.
“In our study, we found that the gut microbiome restrains the progression of melanoma bone lesions in mice by promoting the expansion of intestinal natural-killer (NK) cells and T helper (Th1) cells and enhancing their migration to the tumor site,” Dr. Pal said. “Using oral antibiotics depleted the gut microbiome and reduced the population of intestinal NK cells and Th1 cells. This made the mice more vulnerable to tumor growth. They had a higher melanoma tumor burden than control mice whose gut microbiomes were intact.”
Osteolytic bone metastasis is a complication of malignant melanoma. The researchers hypothesized that depleting the gut microbiota of mice with antibiotics would impact their intestinal immune cells and consequently modify their immune response, resulting in accelerated bone metastasis. They injected B16F10 melanoma cells into the hearts and bones of mice treated with broadspectrum antibiotics. The antibiotic injections, as expected, increased bone metastatic growth in those animals when compared to control mice who had not gotten the treatments.
The research revealed the mechanism of melanoma metastatic growth. Flow cytometric analysis of Peyer’s patches and bone marrow cells inside tumor lesions demonstrated that microbiome depletion inhibited the melanoma-induced expansion of intestinal NK and Th1 cells and their migration from the gut to tumor-bearing bones. Direct measurement of NK and Th1 cell migration using Kaede mice, a strain expressing a photoconvertible fluorescent protein that enables direct tracking of intestinal lymphocytes, found that antibiotics reduced NK and Th1 cell migration from the gut to the tumor site by around eightfold.
When NK cells and Th1 cells leave the gut as part of the body’s immune response, the process is mediated by S1PR5 and S1PR1 receptors. Pharmacological blockade of the cells’ migration via the receptors — involving S1PR5 with NK cells, or S1PR1 with Th1 cells — mimicked the effects of antibiotics. The blockade prevented the expansion of NK cells and Th1 cells in the bone marrow and caused accelerated bone metastasis growth.
The influx of circulating NK and Th1 cells to the tumor site is directed by the chemokine ligand CXCL9, which is expressed by bone marrow cells, and CXCR3, which is expressed by NK and Th1 cells. Global deletion of CXCR3 or antibody neutralization of CXCL9 decreased the frequency of tumor NK and Th1 cells and increased tumor growth.
This study strongly indicates that microbiome modifications induced by antibiotics might have negative clinical consequences not only with melanoma but with other diseases as well, Dr. Pal said. “For example, inflammatory bowel disease, or other gut conditions that create inflammation, can lead to increased Th17 cells, TNF producing cell numbers in the gut, which ultimately has a negative impact on our bone health. Similarly, we have seen that in a murine model of surgical menopause, reduced levels of estrogen cause bacterial metabolites to pass more easily through the gut barrier and hyperactivate the immune system. As a result, the number of intestinal and bone marrow cytokine-producing T cells rises, largely contributing to the development of bone loss.”
Dr. Pal added: “We should be very much careful with our gut microbiome and of the unforeseen adverse consequence of antibiotic regimens. Conversely, probiotics can play a major role to maintain a healthy gut microbiome and better overall health.”
Meeting: American Society for Bone and Mineral Research 2022 Annual Meeting